Current options for the treatment of impetigo in children

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 13, 2005, Pages 2245-2256

  Sladden, Michael J ^a   Johnston, Graham A ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Fusidic acid; Impetigo; Mupirocin; Staphylococcus aureus

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; BACITRACIN; CEFACLOR; CEFALEXIN; CEFOTAXIME; CEFPROZIL; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DICLOXACILLIN; ERYTHROMYCIN; FLUCLOXACILLIN; FUSIDIC ACID; LINEZOLID; METICILLIN; NEOMYCIN; PENICILLIN G; POVIDONE IODINE; PSEUDOMONIC ACID; RIFAMPICIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIUM CULTURE; BLISTER; CHILD; CLINICAL TRIAL; COLITIS; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG POTENTIATION; EPIDERMIS; FOOD DRUG INTERACTION; GLOMERULONEPHRITIS; HUMAN; IMPETIGO; IMPETIGO BULLOSA; LIVER TOXICITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAUSEA; OBSTRUCTIVE JAUNDICE; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; SIDE EFFECT; SKIN EXFOLIATION; SKIN SENSITIZATION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; TOXIC SHOCK SYNDROME; VOMITING;

ANTI-BACTERIAL AGENTS; CHILD; DRUG RESISTANCE, BACTERIAL; ERYTHROMYCIN; FUSIDIC ACID; HUMANS; IMPETIGO; INFANT; MUPIROCIN; RANDOMIZED CONTROLLED TRIALS; STAPHYLOCOCCAL SCALDED SKIN SYNDROME; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES;

EID: 27744608831     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.13.2245     Document Type: Review

References (78)

1. SLADDEN MJ, JOHNSTON GA: Common skin infections in children. Br. Med. J. (2004) 329:95-99.
2. RESNICK SD: Staphylococcal and streptococcal skin infections:pyodermas and toxin-mediated syndromes. In: Textbook of Pediatr. Dermatol. J Harper, A Oranje, N Prose (Eds), Blackwell Science Ltd, Oxford, UK (2000) 369-377.
3. LEE P, ZIPOLI M, WEINBERG A, SWARTZ M, JOHNSON R: Pyodermas: staphylococus aureus, streptococcus, and other Gram-positive bacteria. In: Fitzpatrick's Dermatology in general medicine, I Freedberg, A Eisen, K Wolff, K Austen, L Goldsmith, S Katz (Eds), McGraw-Hill, New York, NY, USA (2003)1856-1867.
4. ERIKSEN NH, ESPERSEN F, ROSDAHL VT, JENSEN K: Carriage of Staphylococcus aureus among 104 healthy persons during a 19-month period. Epidemiol. Infect. (1995) 115(1):51-60.
5. KONING S, VAN BELKUM A, SNIJDERS S et al.: Severity of nonbullous Staphylococcus aureus impetigo in children is associated with strains harboring genetic markers for exfoliative toxin B, Panton-Valentine leukocidin, and the multidrug resistance plasmid pSK41. J. Clin. Microbiol. (2003) 41(7):3017-3021.
6. ONG PY, OHTAKE T, BRANDT C et al.: Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. (2002) 347(15):1151-60.
7. FRITSCH P, ELIAS P. VARGA J: The fate of Staphylococcal exfoliatin in newborn and adult mice. Br. J. Dermatol. (1976) 95(3):275-284.
8. AMAGAI M, MATSUYOSHI N, WANG ZH, ANDL C, STANLEY JR: Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmogtein 1. Nat. Med. (2000). 6(11):1275-1277.
9. RESNICK S, FRITSCH P, ELIAS P: The staphylococcal scalded skin and toxic shock syndromes. In: Physiology, Biochemistry and Molecular Biology of the Skin. L Goldsmith (Ed.), Oxford University Press, Oxford, UK (1991).
10. MONDAY SR, VATH GM, FERENS WA et al.: Unique superantigen activity of staphylococcal exfoliative toxins. J. Immunol. (1999) 162(8):4550-4559.
11. FEINGOLD DS: Staphylococcal and streptococcal pyodermas. Semin. Dermatol. (1993) 12(4):331-335.
12. HLADY WG, MIDDAUGH JP: An epidemic of bullous impetigo in a newborn nursery due to Staphylococcus aureus: epidemiology and control measures. Alaska Med. (1986) 28(4):99-103.
13. HOEGER PH, ELSNER P: Staphylococcal scalded skin syndrome: transmission of exfoliatin-producing Staphylococcus aureus by an asymptomatic carrier. Pediatr. Infect. Dis. J. (1988) 7(5):340-342.
14. DANCER SJ, SIMMONS NA, POSTON SM, NOBLE WC: Outbreak of staphylococcal scalded skin syndrome among neonates. J. Infect. (1988) 16(1):87-103.
15. JOHNSTON GA: Treatment of bullous impetigo and the staphylococcal scalded skin syndrome in infants. Expert Rev. Anti. Infect. Ther. (2004) 2(3):439-446.
16. JOHNSTON GA, GHURA HS, CARTER E, GRAHAM-BROWN RA: Neonatal erythema multiforme major. Clin. Exp. Dermatol. (2002) 27(8):661-664.
17. HOEGER PH: Antimicrobial susceptibility of skin-colonizing S. aureus strains in children with atopic dermatitis. Pediatr. Allergy Immunol. (2004) 15(5):474-477.
18. KONING S, VAN DER WOUDEN JC: Treatment for impetigo. Br. Med. J. (2004) 329(7468):695-696.
19. KONING S, VERHAGEN AP, VAN SUIJLEKOM-SMIT LW, MORRIS A, BUTLER CC, VAN DER WOUDEN JC: Interventions for impetigo. Cochrane Database Syst. Rev. (2004) (2):CD003261.
20. KONING S, VAN SUIJLEKOM-SMIT LW, NOUWEN JL: Fusidic acid cream in the treatment of impetigo in general practice: double blind randomised placebo controlled trial. Br. Med. J. (2002) 324(7331):203-206.
21. COOKSON BD: The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. J. Antimicrob. Chemother. (1998) 41(1):11-18.
22. McLINN S: A bacteriologically controlled, randomized study comparing the efficacy of 2% mupirocin ointment (Bactroban) with oral erythromycin in the treatment of patients with impetigo. J. Am. Acad. Dermatol. (1990) 22(5 Pt 1):883-885.
23. BRADLEY SF, RAMSEY MA, MORTON TM, KAUFFMAN CA: Mupirocin resistance: clinical and molecular epidemiology. Infect. Control. Hosp. Epidemiol. (1995) 16(6):354-358.
24. KATZ BE, FISHER AA: Bacitracin: a unique topical antibiotic sensitizer. J. Am. Acad. Dermatol. (1987) 17(6):1016-1024.
25. GOLLHAUSEN R, ENDERS F, PRZYBILLA B, BURG G, RING J: Trends in allergic contact sensitization. Contact Dermatitis (1988) 18(3):147-154.
26. HEDRICK J: Acute bacterial skin infections in pediatric medicine: current issues in presentation and treatment. Paediatr. Drugs (2003) 5(Suppl. 1):35-46.
27. AMAYA-TAPIA G, AGUIRRE-AVALOS G, ANDRADE-VILLANUEVA J et al.: Once-daily azithromycin in the treatment of adult skin and skin-structure infections. J. Antimicrob. Chemother. (1993) 31(Suppl. E):129-135.
28. FEDER HM Jr, POND KE: Addition of rifampin to cephalexin therapy for recalcitrant staphylococcal skin infections-an observation. Clin. Pediatr. (Phila) (1996) 35(4):205-208.
29. ZAFAR AB, BUTLER RC, REESE DJ, GAYDOS LA, MENNONNA PA: Use of 0.3% triclosan (Bacti-Stat) to eradicate an outbreak of methicillin-resistant Staphylococcus aureus in a neonatal nursery. Am. J. Infect. Control. (1995) 23(3):200-208.
30. HENKEL T, FINLAY J: Emergence of resistance during mupirocin treatment: is it a problem in clinical practice? J. Chemother. (1999) 11(5):331-337.
31. KAUFFMAN CA, TERPENNING MS, HE X et al.: Attempts to eradicate methicillin-resistant Staphylococcus aureus from a long-term-care facility with the use of mupirocin ointment. Am. J. Med. (1993) 94(4):371-378.
32. SPICER WJ: Three strategies in the control of staphylococci including methicillin-resistant Staphylococcus aureus. J. Hosp. Infect. (1984) 5 (Suppl. A):45-49.
33. Report of a combined working party of the British Society for Antimicrobial Chemotherapy, the Hospital Infection Society and the Infection Control Nurses Association. Revised guidelines for the control of methicillin-resistant Staphylococcus aureus infection in hospitals. J. Hosp. Infect. (1998) 39:253-290.
34. LOEB M, MAIN C, WALKER-DILKS C, EADY A: Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization. Cochrane Database Syst. Rev. (2003) (4):CD003340.
35. KNAUER A, FLADERER P, STREMPFL C, KRAUSE R, WENISCH C: Effect of hospitalization and antimicrobial therapy on antimicrobial resistance of colonizing Staphylococcus epidermidis. Wien. Klin. Wochenschr. (2004) 116(14):489-494.
36. TURNIDGE J, COLLIGNON P: Resistance to fusidic acid. Int. J. Antimicrob. Agents (1999) 12(Suppl. 2):S35-S44.
37. DOBIE D, GRAY J: Fusidic acid resistance in Staphylococcus aureus. Arch. Dis. Child. (2004) 89(1):74-77.
38. BESIER S, LUDWIG A, BRADE V, WICHELHAUS TA: Molecular analysis of fusidic acid resistance in Staphylococcus aureus. Mol. Microbiol. (2003) 47(2):463-469.
39. BROWN EM, WISE R: Fusidic acid cream for impetigo. Fusidic acid should be used with restraint. Br. Med. J. (2002) 324(7350):1394.
40. NISHIJIM S, OHSHIMA S, HIGASHIDA T, NAKAYA H, KUROKAWA I: Antimicrobial resistance of Staphylococcus aureus isolated from impetigo patients between 1994 and 2000. Int. J. Dermatol. (2003) 42(1):23-25.
41. KESAH C, BEN REDJEB S, ODUGBEMI TO et al.: Prevalence of methicillin-resistant Staphylococcus aureus in eight African hospitals and Malta. Clin. Microbiol. Infect. (2003) 9(2):153-156.
42. KIM HB, JANG HC, NAM HJ et al.: In vitro activities of 28 antimicrobial agents against Staphylococcus aureus isolates from tertiary-care hospitals in Korea: a nationwide survey. Antimicrob. Agents Chemother. (2004) 48(4):1124-1127.
43. OSTERLUND A, EDEN T, OLSSON-LILJEQUIST B et al.: Clonal spread among Swedish children of a Staphylococcus aureus strain resistant to fusidic acid. Scand. J. Infect. Dis. (2002) 34(10):729-734.
44. TVETEN Y, JENKINS A, KRISTIANSEN BE: A fusidic acid-resistant clone of Staphylococcus aureus associated with impetigo bullosa is spreading in Norway. J. Antimicrob. Chemother. (2002) 50(6):873-876.
45. O'NEILL AJ, LARSEN AR, HENRIKSEN AS, CHOPRA I: A fusidic acid-resistant epidemic strain of Staphylococcus aureus carries the fusB determinant, whereas fusA mutations are prevalent in other resistant isolates. Antimicrob. Agents Chemother. (2004) 48(9):3594-3597.
46. MASON BW, HOWARD AJ, MAGEE JT: Fusidic acid resistance in community isolates of methicillin-susceptible Staphylococcus aureus and fusidic acid prescribing. J. Antimicrob. Chemother. (2003) 51(4):1033-1036.
47. MASON BW, HOWARD AJ: Fusidic acid resistance in community isolates of methicillin susceptible Staphylococcus aureus and the use of topical fusidic acid: a retrospective case-control study. Int. J. Antimicrob. Agents. (2004) 23(3):300-303.
48. WILKINSON JD: Fusidic acid in dermatology. Br. J. Dermatol. (1998) 139(Suppl. 53):37-40.
49. SHAH M, MOHANRAJ M: High levels of fusidic acid-resistant Staphylococcus aureus in dermatology patients. Br. J. Dermatol. (2003) 148(5):1018-1020.
50. SULE O, BROWN N, BROWN DF, BURROWS N: Fusidic acid cream for impetigo. Judicious use is advisable. Br. Med. J. (2002) 324(7350):1394.
51. STODDART B, COLLYNS T, DENTON M: Fusidic acid cream for impetigo. Problem may be clinically important. Br. Med. J. (2002) 324(7350):1394.
52. RAVENSCROFT JC, LAYTON A, BARNHAM M: Observations on high levels of fusidic acid resistant Staphylococcus aureus in Harrogate, North Yorkshire, UK. Clin. Exp. Dermatol. (2000) 25(4):327-330.
53. EL-ZIMAITY D, KEARNS AM, DAWSON SJ, PRICE S, HARRISON GA: Survey, characterization and susceptibility to fusidic acid of Staphylococcus aureus in the Carmarthen area. J. Antimicrob. Chemother. (2004) 54(2):441-446.
54. AXELSSON I. Treatment of impetigo: save mupirocin. Br. Med. J. (2004) 329(7472):979.
55. ZAKRZEWSKA-BODE A, MUYTJENS HL, LIEM KD, HOOGKAMP-KORSTANJE JA: Mupirocin resistance in coagulase-negative staphylococci, after topical prophylaxis for the reduction of colonization of central venous catheters. J. Hosp. Infect. (1995) 31(3):189-193.
56. MOY JA, CALDWELL-BROWN D, LIN AN, PAPPA KA, CARTER DM: Mupirocin-resistant Staphylococcus aureus after long-term treatment of patients with epidermolysis bullosa. J. Am. Acad. Dermatol. (1990) 22(5 Pt 1):893-895.
57. LESKI TA, GNIADKOWSKI M, SKOCZYNSKA A, STEFANIUK E, TRZCINSKI K, HRYNIEWICZ W: Outbreak of mupirocin-resistant staphylococci in a hospital in Warsaw, Poland, due to plasmid transmission and clonal spread of several strains. J. Clin. Microbiol. (1999) 37(9):2781-2788.
58. SCHMITZ FJ, LINDENLAUF E, HOFMANN B et al.: The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals. J. Antimicrob. Chemother. (1998) 42(4):489-495.
59. DESHPANDE LM, FIX AM, PFALLER MA, JONES RN; SENTRY Antimicrobial Surveillance Program Participants Group: Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods. Diagn. Microbiol. Infect. Dis. (2002) 42(4):283-290.
60. KOTRA L, SAMAMA J, MOBASHERY S: Beta-lactamases and resistance to beta-lactam antibiotics. In: Bacterial resistance to antimicrobials. KS Lewis, AA Taber, HW Wax, RG (Eds), Marcel Decker, New York, NY, USA (2002) 123-160.
61. SAMAHA-KFOURY J, ARAJ G: Recent developments in beta lactamases and extended spectrum beta lactamases. Br. Med. J. (2003) 327:1209-1213.
62. DUCKWORTH G: Controlling methicillin resistant Staphylococcus aureus. Br. Med. J. (2003) 327(7425):1177-1178.
63. HRYNIEWICZ W: Epidemiology of MRSA. Infection (1999) 27(Suppl. 2):S13-S16.
64. YAMAGUCHI T, YOKOTA Y, TERAJIMA J et al.: Clonal association of Staphylococcus aureus causing bullous impetigo and the emergence of new methicillin-resistant clonal groups in Kansai district in Japan. J. Infect. Dis. (2002) 185(10):1511-1516.
65. GOSBELL IB: Methicillin-resistant Staphylococcus aureus: impact on dermatology practice. Am. J. Clin. Dermatol. (2004) 5(4):239-259.
66. BAGGETT HC, HENNESSY TW, LEMAN R et al.: An outbreak of community-onset methicillin-resistant Staphylococcus aureus skin infections in southwestern Alaska. Infect. Control. Hosp. Epidemiol. (2003) 24(6):397-402.
67. MUNCKHOF WJ, KLEINSCHMIDT SL, TURNIDGE JD: Resistance development in community-acquired strains of methicillin-resistant Staphylococcus aureus: an in vitro study. Int. J. Antimicrob. Agents. (2004) 24(6):605-608.
68. PERRY CM, JARVIS B: Linezolid: a review of its use in the management of serious Gram-positive infections. Drugs (2001) 61(4):525-551.
69. STEVENS DL, HERR D, LAMPIRIS H et al.: Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. (2002) 34(11):1481-1490.
70. SCHWEIGER ES, SCHEINFELD NS, TISCHLER HR, WEINBERG JM: Linezolid and quinupristin/dalfopristin: novel antibiotics for Gram-positive infections of the skin. J. Drugs Dermatol. (2003) 2(4):378-383.
71. SCHWEIGER ES, WEINBERG JM: Novel antibacterial agents for skin and skin structure infections. J. Am. Acad. Dermatol. (2004) 50(3):331-340.
72. HURDLE JG, O'NEILL AJ, CHOPRA I: Anti-staphylococcal activity of indolmycin, a potential topical agent for control of staphylococcal infections. J. Antimicrob. Chemother. (2004) 54(2):549-552.
73. CUTLER RR, WILSON P: Antibacterial activity of a new, stable, aqueous extract of allicin against methicillin-resistant Staphylococcus aureus. Br. J. Biomed. Sci. (2004) 61(2):71-74.
74. SATO M, TANAKA H, YAMAGUCHI R, KATO K, ETOH H: Synergistic effects of mupirocin and an isoflavanone isolated from Erythrina variegata on growth and recovery of methicillin-resistant Staphylococcus aureus. Int. J. Antimicrob. Agents. (2004) 24(3):241-246.
75. DRYDEN MS, DAILLY S, CROUCH M: A randomized, controlled trial of tea tree topical preparations versus a standard topical regimen for the clearance of MRSA colonization. J. Hosp. Infect. (2004) 56(4):283-286.
76. AL-SULAMI AA, AL-RUBIAY KK, AFFAT AM: An inhibitor of Staphylococcus aureus exfoliative toxin. East Mediterr. Health J. (2001) 7(1-2):121-127.
77. COYLE EA: Targeting bacterial virulence: the role of protein synthesis inhibitors in severe infections. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy (2003) 23(5):638-642
78. CIFTCI E, GURIZ H, AYSEV AD: Mupirocin versus terbinafine in impetigo. Indian J. Pediatr. (2002) 69(8):679-682.